Latest Breaking News On - Philipj rosenfeld - Page 1 : comparemela.com
World s Most Influential People in Ophthalmology | Coral Gables Community News#
communitynewspapers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from communitynewspapers.com Daily Mail and Mail on Sunday newspapers.
AI in retina moving toward real-world practice
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nine Bascom Palmer doctors named to Power List Honoring Top Women in Ophthalmology
News provided by
Share this article
Share this article
MIAMI, April 1, 2021 /PRNewswire/ Nine esteemed ophthalmologists at Bascom Palmer Eye Institute were selected for
The Ophthalmologist Power List 2021, which honors the world s 100 most influential women in the field of ophthalmology.
Audina M. Berrocal, M.D., Hilda Capo, M.D., Janet L. Davis, M.D., M.B.A., Kendall E. Donaldson, M.D., M.S., Anat Galor, M.D., Alana Grajewski, M.D., Ranya G. Habash, M.D., Carol L. Karp, M.D., and Sonia Yoo, M.D., were named to the Power List as published in
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
December 23, 2020 GMT
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) to test the efficacy and safety of conbercept intravitreal injection in the treatment of neovascular age-related macular degeneration (“nAMD”). PANDA trials recently reached an important milestone by completing 36-week primary endpoint visits of enrolled patients. Conbercept is expected to launch globally in 2023, bringing a new treatment option to patients.